Manulife Financial (MFC.TO) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Manulife Financial (MFC.TO)

57.19

+0.15 (0.26%)

as of Jun 26, 2026, 8:00:00 pm Market Open.

1634 watching

Investor Insights

Jun 26, 2026, 12:00 am

This summary was created by AI, based on 28 opinions in the last 12 months.

Manulife Financial (MFC) has garnered mixed reviews from experts, reflecting a range of perspectives on its current standing and future potential. Several analysts highlight the company's strong dividend yield and its robust performance in Asia, suggesting it may be a worthwhile long-term investment, particularly for those seeking income rather than growth. However, concerns regarding earnings fluctuations, market pullbacks, and comparisons with peers like Sun Life Financial indicate that MFC may not be as attractive as other options in the life insurance sector. Many experts recognize the potential for capital appreciation, yet they caution that the stock faces headwinds, especially when considering broader market dynamics and the performance of similar financial institutions. There is a prevailing sentiment that the stock remains a reliable choice, albeit needing careful monitoring amidst potential market corrections.

Consensus

Hold

Valuation

Fair Value

Similar

SLF

TOP PICK

Was startled when they cut the dividend. There were two issues – few ink stains on blotter from prior management and had to decide whether to issue equity now or sit back and get shareholder’s rather if market when down.

STRONG BUY

Did an equity issue that investors felt uncomfortable with but he thinks it was the right thing to do. This increased capital so they can make good acquisitions. Have one of the best franchises in Canada as well as a global franchise. Great growth prospects.

DON'T BUY

Going through a digestion period. They cut the dividend and issued new shares to raise a lot of money, which cheesed a lot of people off. Negative sentiment will take some time to wear off.

COMMENT

Have guided that normalized earnings would be $1.85 per share making it under 10X earnings for the next year. You have to be patient. Expecting a cloud will continue to hang over the stock for a while.

COMMENT

Didn't like the issue of 2.5 billion of new shares. Overly conservative in raising money and diluting existing shareholders. Great exposure to Asia, which is the main thing that differentiates it from their peers. Given the earnings outlook it's a great buy but will be in the penalty box until they start spending some of that money.

WAIT

On a current basis, it is kind of absolute dog. It will remedy itself. At the current time, Sun Life (SLF-T) is better with a 5% dividend versus 3.5% and a market cap that is 2/3 better shape. It might be nearing the bottom that way for a while.

WEAK BUY

It is the premier North American life insurance company. One of the attractions is the operation in the far east. They could benefit from distressed asset purchases. Variable annuity product makes them a leveraged play on the US market. If there is another big correction in the market, they are still very vulnerable.

TOP PICK

Sold half his position when they cut the dividend but at $18 it is trading under 10 X earnings. Great long-term business. Will probably make Asian acquisitions.

HOLD

Feels the worst is over for them but wouldn't add to a position. Trading close to BV. In the penalty box for a while.

BUY

Below $19 there is only upside to the name. SLF would be his pick.

TOP PICK

Stumbled on raising capital and what they had in their guaranteed products. Lots of capital and will make acquisitions. Better growth in lifecos than in banks going forward. Potential to earn $2.50-$3 a share 2 years out, which would put the stock into the mid-$30's.

HOLD

Cut the dividend and then followed up by issuing more shares creating a great deal of dilution. Management is trying to create a bulletproof balance sheet. Doesn't think they have entirely lost the potential upside in an improving market. 2.8% yield.

DON'T BUY

Large surprise equity issue recently, which has not been cleared yet, which is why the share price is trading under the issue price. Lifecos in Canada are going to be in a pretty tight trading range until there is some clarity on the new regulations.

COMMENT

Feels there is valuation support at these levels.

DON'T BUY

Not a big fan of this. Likes companies that do well in a tough environment and will do well going forward. Due to product mixes they were in a tough spot. Economy has challenges ahead and this would be one of the first that has to come back to the market again.

Showing 1,546 to 1,560 of 2,281 entries

Most Recent Experts

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Kevin Simpson

Capital Wealth Planning

Bryn Talkington

Requisite Capital Management

Andrey Omelchak

LionGuard Capital Management

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Manulife Financial (MFC.TO)